Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus CEFOTAXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus CEFOTAXIME SODIUM.
CEFIZOX vs CEFOTAXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-1A and PBP-3, leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life is 0.9-1.5 hours in adults with normal renal function; prolonged to 2.5-10 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-6 hours.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Renal (50-60% unchanged), biliary (5-10%), with approximately 20-30% metabolized to desacetylcefotaxime (also renally eliminated). Total renal elimination of parent drug and metabolite accounts for >80%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic